Condensed Consolidated Financial Statement Details (Tables)

9 Months Ended

Sep. 30, 2024

Inventory Disclosure [Abstract]

Schedule of Inventory

Inventory consists of the following (in thousands):

	September 30, 2024		December 31, 2023
Raw materials	$	—	$	1,861
Work-in-process		—		12,880
Finished goods		—		1,360
Total inventory, net	$	—	$	16,101

Schedule of Other Current Assets

Other current assets consist of the following (in thousands):

	September 30, 2024		December 31, 2023
Prepaid research and development expenses	$	3,960	$	4,325
Interest and other non-trade receivables		2,123		1,047
Other prepaid expenses		2,850		4,407
Total other current assets	$	8,933	$	9,779

Assets Held for Sale

As of September 30, 2024, assets held for sale consist of the following:

	September 30, 2024
Accounts receivable	$	1,746
Inventory, net		16,889
Property, plant and equipment, net		11,386
Contract asset		3,032
Total assets held for sale	$	33,053

Schedule of Property, Plant and Equipment

Property, plant and equipment consists of the following (in thousands):

	September 30, 2024			December 31, 2023
Building and leasehold improvements	$	3,834		$	43,184
Computer equipment and computer software		14,615			22,438
Manufacturing equipment		—			24,315
Laboratory equipment		616			14,537
Furniture, fixtures and other		59			541
Depreciable property, plant and equipment at cost		19,124			105,015
Less: accumulated depreciation		(15,659	)		(86,898	)
Depreciable property, plant and equipment, net		3,465			18,117
Construction in process		138			739
Property, plant and equipment, net	$	3,603		$	18,856

Schedule of Accrued Expenses

Accrued expenses consist of the following (in thousands):

	September 30, 2024		December 31, 2023
Accrued compensation	$	7,007	$	5,553
Accrued research and development expenses		17,916		10,118
Accrued contract termination costs		3,151		3,020
Other accrued expenses		4,303		3,471
Total accrued expenses	$	32,377	$	22,162

Schedule of Liability Related to Sale of Potential Future Royalties

The following is a reconciliation of the changes in our liabilities related to the sales of future royalties for the nine months ended September 30, 2024 (in thousands):

	Nine Months Ended September 30, 2024
	2012 Purchase and Sale Agreement			2020 Purchase and Sale Agreement			Total
Liabilities related to the sales of future royalties, net – beginning balance	$	24,217		$	88,408		$	112,625
Non-cash royalty revenue		(19,007	)		(29,022	)		(48,029	)
Non-cash interest expense		4,940			13,019			17,959
Amortization of transaction costs		—			274			274
Proceeds from the Amendment		—			15,000			15,000
Liabilities related to the sales of future royalties, net – ending balance	$	10,150		$	87,679		$	97,829

Schedule of Accumulated Other Comprehensive Income (Loss)

The following table summarizes the changes in accumulated other comprehensive income (loss) by component (in thousands):

	Foreign currency translation			Available-for-sale securities			Accumulated Other Comprehensive Income
Balance at December 31, 2023	$	30		$	50		$	80
Foreign currency translation adjustments		(8	)		—			(8	)
Unrealized gain (loss) on available-for-sale securities		—			(475	)		(475	)
Balance at March 31, 2024	$	22		$	(425	)	$	(403	)
Foreign currency translation adjustments		(1	)		—			(1	)
Unrealized gain (loss) on available-for-sale securities		—			(90	)		(90	)
Balance at June 30, 2024	$	21		$	(515	)	$	(494	)
Foreign currency translation adjustments		(28	)		—			(28	)
Unrealized gain (loss) on available-for-sale securities		—			877			877
Balance at September 30, 2024	$	(7	)	$	362		$	355

	Foreign currency translation			Available-for-sale securities			Accumulated Other Comprehensive Income
Balance at December 31, 2022	$	(5,131	)	$	(1,776	)	$	(6,907	)
Foreign currency translation adjustments		139			—			139
Unrealized gain (loss) on available-for-sale securities		—			1,087			1,087
Balance at March 31, 2023	$	(4,992	)	$	(689	)	$	(5,681	)
Foreign currency translation adjustments		13			—			13
Unrealized gain (loss) on available-for-sale securities		—			244			244
Reclassification adjustments to income		(1,026	)		—			(1,026	)
Balance at June 30, 2023	$	(6,005	)	$	(445	)	$	(6,450	)
Foreign currency translation adjustments		(98	)		—			(98	)
Unrealized gain (loss) on available-for-sale securities		—			196			196
Balance at September 30, 2023	$	(6,103	)	$	(249	)	$	(6,352	)